Equity Research Analysis: ChromaDex Corp. (NAGE)
|Blank Capital Research Unit|Spot: $5.10
Price$5.10
Composite Score49.7/100
RatingREDUCE (2★)
Rank#2048 OF 7,333
Market Cap$744M
IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#2048
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$744M
Robert N. Fried
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. It researches on nicotinamide adenine dinucleotide (NAD+) and develops and commercializes proprietary-based ingredient technologies. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform.
Headcount
120
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = NAGE ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$NAGE ChromaDex Corp. | 50 | 81 | 59 | 30 | 25.6x | 27.3x | 21.4% | 15.4% | 64.1% | 11.2% | 12.3% | 49.5% | 0.0% | 39.0x | $744M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
ChromaDex Corp. (NAGE) receives a "Reduce" rating with a composite score of 49.7/100. It ranks #2048 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
HQ Base
IRVINE, California
Lagging peers — losers tend to keep underperforming
Fair valuation relative to peers
High profitability & efficiency — strong quality floor supports entry
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for NAGE.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 81 | 93 | -12DRAG |
| MOMENTUM | 30 | 18 | +12ALPHA |
| VALUATION | 59 | 50 | +9ALPHA |
| INVESTMENT | 33 | 53 | -20DRAG |
| STABILITY | 40 | 29 | +11ALPHA |
| SHORT INT | 26 | 14 | +12ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy 21.4% (sector -1.9%)
GM 64% vs sector 44%, OM 11% vs sector 3%
Capital turnover N/A, R&D intensity 4.8%
Rev growth 49%, 10yr history
Interest coverage N/A, Net debt/EBITDA -15.2x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate ChromaDex Corp. (NAGE) as a Reduce with a composite score of 49.7/100 at a current price of $5.10. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential.
ChromaDex Corp. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 49.7/100 places it at rank #2048 in our full universe.
Narrow
High
Standard
Fair Value
Gross margins of 64% signal strong pricing power.
Returns on equity of 21.4% exceed cost of capital.
Stable competitive position in a defensive sector.
Weak momentum suggests persistent institutional selling pressure.
Vulnerability to macroeconomic shocks and interest rate volatility.
ChromaDex Corp. represents a reduce based on multi-factor quantitative performance.
ChromaDex Corp. receives a Reduce rating from our analysis, with a composite score of 49.7/100 and 2 out of 5 stars, ranking #2048 out of 7,333 stocks. NAGE's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
NAGE earns a quality score of 81/100, indicating above-average business quality. The company reports a return on equity of 21.4% (sector avg: -1.9%), gross margins of 64.1% (sector avg: 44.1%), net margins of 12.3% (sector avg: 1.0%). Companies in this tier generally demonstrate consistent profitability and efficient capital deployment, though they may face some competitive pressure.
NAGE's value score of 59/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include a P/E ratio of 25.64x, an EV/EBITDA of 27.33x, a P/B ratio of 5.49x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
ChromaDex Corp.'s investment score of 33/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 49.5% vs. a sector average of 6.7% and a return on assets of 15.4% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
NAGE is currently showing below-average momentum at 30/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at 49.5% year-over-year, while a beta of 1.54 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
NAGE's stability score of 40/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.54 and a debt-to-equity ratio of 39.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
ChromaDex Corp.'s short interest score of 26/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include high market sensitivity (beta: 1.54), elevated leverage (D/E: 39.00x), small-cap liquidity risk. At $744M (small-cap), NAGE carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
ChromaDex Corp. is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #2048 of 7,333 overall (72nd percentile). Key comparisons include ROE of 21.4% exceeding the -1.9% sector median and operating margins of 11.2% above the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While NAGE currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Short Int. (26) would have the largest impact on the composite score.
EV/EBITDA 138% ABOVE SECTOR MEDIAN
ROE 1226% BELOW SECTOR MEDIAN
Gross Margin 46% ABOVE SECTOR MEDIAN (FAVORABLE)
LOS ANGELES, February 09, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces it is the headlining sponsor of the inaugural NAD for Health: Opportunities & Challenges scientific meeting hosted by the University of Copenhagen, taking place March 23–25, 2026 at the Royal Danish Academy of Sciences and Letters in central Copenhagen. Space is limited and registration is required;
Niagen Bioscience, Inc. (NASDAQ: NAGE) previously announced it will report fourth quarter and fiscal 2025 results and host an investor conference call on March 4, 2026, including a general business update following the release of its earnings after market close. The company’s position as a leading NAD+ player, with FDA-recognized Niagen® and defended patents around nicotinamide riboside, highlights a reinforced regulatory moat and product pipeline momentum. We’ll now examine how the upcoming...
As the U.S. stock market rebounds from recent turbulence, driven by geopolitical tensions and economic policy shifts, investors are closely monitoring growth companies that exhibit strong fundamentals and resilience. In this context, high insider ownership combined with robust revenue growth can be a compelling indicator of confidence in a company's future prospects, making it an attractive consideration for those navigating today's complex market landscape.
Recent coverage around Niagen Bioscience (NAGE) has focused on upcoming launches with major consumer product partners and fresh clinical data tied to its FDA recognized nicotinamide riboside, which has pushed the stock back onto investors’ watchlists. See our latest analysis for Niagen Bioscience. Despite the recent excitement around new partner launches and clinical readouts, Niagen Bioscience’s share price has pulled back. The 30 day share price return shows a 24.11% decline and the 90 day...
Niagen Bioscience recently drew investor attention as its flagship healthy aging supplement, TRU NIAGEN, expanded distribution through direct e-commerce channels and major online platforms such as Amazon. This development highlights how the company is seeking to harness rising demand for science-backed anti-aging solutions, supported by optimistic analyst coverage of its business model. We will now examine how TRU NIAGEN’s broader online reach could shape Niagen Bioscience’s investment...
Above 50MA
37.18%
Net New Highs
+51081